rolapitant

an anti-emetic agent; structure in first source

Also Known As:

(5S,8S)-8-(((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro(4.5)decan-2-one; 8-((1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro(4,5)decan-2-one; SCH 619734; Varubi

Networked: 54 relevant articles (16 outcomes, 16 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Spiro Compounds: 2
      - rolapitant: 54
Polycyclic Compounds: 6
- Spiro Compounds: 2
  - rolapitant: 54

Experts

1.	Arora, Sujata: 14 articles (01/2019 - 09/2015)
2.	Kansra, Vikram: 11 articles (10/2019 - 09/2015)
3.	Wang, Jing: 11 articles (10/2019 - 12/2017)
4.	Wang, Xiaodong: 11 articles (10/2019 - 12/2017)
5.	Zhang, Zhi-Yi: 11 articles (10/2019 - 12/2017)
6.	Navari, Rudolph M: 8 articles (12/2019 - 01/2015)
7.	Lu, Sharon: 8 articles (03/2019 - 12/2017)
8.	Powers, Dan: 8 articles (03/2019 - 04/2016)
9.	Rapoport, Bernardo L: 6 articles (07/2018 - 09/2015)
10.	Rapoport, Bernardo: 5 articles (06/2017 - 11/2015)

Related Diseases

1.	Vomiting 04/01/2016 - "Over cycles 1-6, time-to-first emesis was significantly longer with rolapitant than with control (p < 0.001). " 04/01/2011 - "Groups assigned to rolapitant 20-mg, 70-mg, and 200-mg had a higher incidence of no emesis in comparison with placebo at 24 hours after surgery. " 10/01/2019 - "A slight positive trend was observed between rolapitant exposure and efficacy (ie, complete response defined as no emesis and no use of rescue medication) in the delayed phase of CINV (>24-120 hours after chemotherapy). " 09/01/2015 - "Role of rolapitant in chemotherapy-induced emesis." 01/01/2017 - "In the pooled HEC studies, rolapitant significantly improved the FLIE total score (114.5 vs 109.3, p < 0.001), nausea score (55.3 vs 53.5, p < 0.05), and vomiting score (59.2 vs 55.8, p < 0.001) versus control; similar results were observed in the MEC/AC study for FLIE total score (112.7 vs 108.6, p < 0.001), nausea score (54.1 vs 52.3, p < 0.05), and vomiting score (58.6 vs 56.3, p < 0.001). "
2.	Nausea 07/01/2018 - "We evaluated the efficacy of the long-acting NK-1RA rolapitant in preventing chemotherapy-induced nausea using post hoc analyses of data from 3 phase 3 trials. " 07/01/2018 - "Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy." 01/01/2017 - "In the pooled HEC studies, rolapitant significantly improved the FLIE total score (114.5 vs 109.3, p < 0.001), nausea score (55.3 vs 53.5, p < 0.05), and vomiting score (59.2 vs 55.8, p < 0.001) versus control; similar results were observed in the MEC/AC study for FLIE total score (112.7 vs 108.6, p < 0.001), nausea score (54.1 vs 52.3, p < 0.05), and vomiting score (58.6 vs 56.3, p < 0.001). " 04/01/2016 - "Post hoc analyses of pooled safety and efficacy data from the four trials were performed for cycles 2-6. Significantly more patients receiving rolapitant than control reported no emesis or interfering nausea (combined measure) in cycles 2 (p = 0.006), 3 (p < 0.001), 4 (p = 0.001), and 5 (p = 0.021). " 04/01/2016 - "Over multiple cycles of MEC or HEC, rolapitant provided superior CINV protection and reduced emesis and nausea interfering with daily life compared with control and remained well tolerated."
3.	Neoplasms (Cancer) 03/01/2016 - "This review will detail the clinical efficacy and safety of rolapitant in the treatment of patients with cancer receiving highly or moderately emetogenic chemotherapy. " 01/01/2019 - "A Phase 1 Assessment of the QT Interval in Healthy Adults Following Exposure to Rolapitant, a Cancer Supportive Care Antiemetic." 01/01/2017 - "We reviewed recent post hoc analyses of clinical trial data demonstrating that rolapitant is efficacious in the control of CINV in patient populations with specific tumor types, namely, breast cancers, gastrointestinal/colorectal cancers, and lung cancers. " 09/01/2015 - "Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials." 09/01/2015 - "Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial."
4.	Headache (Headaches) 01/01/2019 - "The most common rolapitant-related treatment-emergent adverse events were headache, dry mouth, and dizziness, which were predominantly mild in severity. " 09/01/2015 - "The incidence of adverse events was similar in the rolapitant and control groups, with the most frequently reported treatment-related treatment-emergent adverse events being fatigue, constipation, and headache. " 09/01/2015 - "The most commonly reported treatment-related treatment-emergent adverse events in the rolapitant versus active control groups were headache (three [<1%] vs two [<1%]), hiccups (three [<1%] vs four [<1%]), constipation (two [<1%] vs three [<1%]), and dyspepsia (two [<1%] vs three [<1%]). " 01/01/2016 - "Improvement in the prevention of delayed emesis has occurred with the neurokinin (NK)-1 receptor antagonists aprepitant, netupitant, and rolapitant with mild headache, constipation, hiccups, and fatigue the most commonly reported adverse events. "
5.	Constipation 09/01/2015 - "The incidence of adverse events was similar in the rolapitant and control groups, with the most frequently reported treatment-related treatment-emergent adverse events being fatigue, constipation, and headache. " 09/01/2015 - "The most commonly reported treatment-related treatment-emergent adverse events in the rolapitant versus active control groups were headache (three [<1%] vs two [<1%]), hiccups (three [<1%] vs four [<1%]), constipation (two [<1%] vs three [<1%]), and dyspepsia (two [<1%] vs three [<1%]). " 01/01/2016 - "Improvement in the prevention of delayed emesis has occurred with the neurokinin (NK)-1 receptor antagonists aprepitant, netupitant, and rolapitant with mild headache, constipation, hiccups, and fatigue the most commonly reported adverse events. "

Related Drugs and Biologics

1.	Dexamethasone (Maxidex)
2.	Neurokinin-1 Receptor Antagonists
3.	Anthracyclines
4.	Cyclophosphamide (Cytoxan)
5.	Neurokinin-1 Receptors (Neurokinin 1 Receptor)
6.	Cisplatin (Platino)
7.	Granisetron (Kytril)
8.	Carboplatin (JM8)
9.	netupitant
10.	Antiemetics

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Intravenous Infusions
4.	Oral Administration